Comparing the strength of ERK signaling—baseline, elevated, or excessive in unaffected, RASopathy, or oncology contexts, respectively—informs the choice of MEKi dosing, with the aim to normalize signaling using a low or moderate dose of inhibitor over an extended time course, rather than to terminate signaling (and cancer) with an acute high dose therapy. Here, MAPK1 is linked to RASopathy.